Core 1 and extended core 1 O-glycan epitopes on Carcinoembryonic antigen-related cell adhesion molecule 5 and 6 variants (Core 1 O-glycan on CEACAM5/6)

Core 1 and extended core 1 O-glycan epitopes on CEACAM5 (Carcinoembryonic antigen-related cell adhesion molecule 5) and CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6) represent tumor-specific post-translational modifications. While the protein scaffolds CEACAM5 and CEACAM6 are well-known oncofetal antigens, their specific glycosylation patterns in malignant tissues—characterized by truncated or extended Core 1 O-glycans—distinguish them from the forms found in healthy tissues (UniProt P06731, P40199). These glyco-epitopes play a critical role in cancer progression by facilitating cell-cell adhesion, promoting metastasis, and contributing to immune evasion by interacting with lectins on immune cells (PubMed: 30213805). Therapeutic strategies, such as the monoclonal antibody NCAB001, specifically target these glycoforms to achieve higher tumor selectivity compared to targeting the protein backbone alone. This approach aims to minimize systemic toxicity while maximizing the destruction of cancer cells through mechanisms like antibody-dependent cellular cytotoxicity (ADCC).

Other names

Tumor-associated O-glycan epitopes on CEACAM5/6Core 1 O-glycan CEACAM5Core 1 O-glycan CEACAM6Glyco-CEACAM5Glyco-CEACAM6Carcinoembryonic antigen-related cell adhesion molecule 5/6 glycoform

Antibody-dependent cellular cytotoxicity (ADCC), Antibody-dependent cellular phagocytosis (ADCP), and direct inhibition of cell adhesion signaling.